Drug intelligence / Profile preview

EcoActive

Development stage: Phase 2
Lead developer: Intralytix
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**EcoActive** is an investigational, orally administered seven-lytic-bacteriophage cocktail developed by Intralytix for inactive Crohn's disease. It is designed to selectively infect and lyse adherent-invasive *Escherichia coli* (AIEC), a Crohn's disease-associated bacterial pathotype, thereby reducing intestinal AIEC burden rather than broadly suppressing the microbiota. EcoActive is being evaluated in the randomized, double-blind, placebo-controlled Phase 1/2a trial NCT03808103. ([intralytix.com](https://www.intralytix.com/clinical-trial/1))

Other names: EcoActive

Targets

FimH (Type 1 fimbrial adhesin)

Beyond the preview

Go deeper on EcoActive.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcoActive.

Explore the full profile